Press Releases

Press Releases

    Date Title View
    09/09/19
    Summary ToggleHorizon Therapeutics plc Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED)
    PDF Version
    08/28/19
    Summary ToggleHorizon Therapeutics plc Names Andy Pasternak Executive Vice President, Chief Business Officer
    PDF Version
    08/19/19
    Summary ToggleAmerican Journal of Ophthalmology (AJO) Publishes Review Highlighting Lack of Treatments for Active Thyroid Eye Disease (TED)
    PDF Version
    08/19/19
    Summary ToggleHorizon Therapeutics plc to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference
    PDF Version
    08/14/19
    Summary ToggleHorizon Therapeutics plc Collaborates with Rare Disease Advocates to Elevate Resources and Shared Experiences Through Launch of #RAREis™ Community Website
    PDF Version
    08/07/19
    Summary ToggleHorizon Therapeutics plc Reports Strong Second-Quarter 2019 Results; Increases Full‐Year 2019 Net Sales and Adjusted EBITDA Guidance
    08/01/19
    Summary ToggleHorizon Therapeutics plc Announces Teprotumumab Expanded Access Program
    PDF Version
    08/01/19
    Summary ToggleHorizon Therapeutics plc Appoints Dr. Sue Mahony to Board of Directors
    PDF Version
    07/25/19
    Summary ToggleHorizon Therapeutics plc Wins International CSR Excellence Award for Partnership with Perspectives Math and Science Academy
    PDF Version
    07/18/19
    Summary ToggleHorizon Therapeutics plc Announces U.S. FDA Acceptance of its New Drug Application to Make PROCYSBI® (Cysteamine Bitartrate) Available as Oral Granules in Packets
    PDF Version
    Displaying 1 - 10 of 455 results